Deep learning tools for protein design can also be used to create molecules that bind to them. Certain peptides, such as intrinsically disordered proteins (IDPs), are challenging to target due to their variable nature. However, scientists from the lab of Nobel laureate David Baker have developed a method to generate binders for IDPs by searching the world’s largest protein database with their AI-powered tool RFdiffusion. Read More
Mabwell (Shanghai) Bioscience Co. Ltd. announced that its Cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC), 7MW-4911, has received IND clearance to initiate clinical trials from both the U.S. FDA and China's National Medical Products Administration (NMPA).
Neuroinflammation is a hallmark of Alzheimer’s disease (AD), driven in part by chronic microglial activation and elevated pro-inflammatory cytokines, which contribute to neuronal damage and cognitive decline. Targeting microglial activity has emerged as a promising therapeutic approach. Read More
Cassava Sciences Inc. a has reported positive preclinical results of a study evaluating simufilam in a mouse model of tuberous sclerosis complex (TSC)-related epilepsy. TSC is a rare genetic disorder resulting from a mutation in the TSC1 or TSC2 gene. Read More
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. NMEs include compounds chosen for further pharmacological evaluation or as clinical candidates; new leads whose structural optimization could provide new therapeutic agents; new additions to the structural diversity of known mechanistic classes of drugs; and new pharmacological tools for investigating drug targets. Read More
In a recent study in the Journal of Translational Medicine, researchers from Azrieli Research Center (Canada) and collaborating institutions hypothesized that the dysregulation of SMPDL3B may be involved in myalgic encephalomyelitis (ME) progression, and investigated its role and clinical relevance in ME pathophysiology. Read More
Researchers from Suven Life Sciences Ltd. have presented results on the evaluation of the pharmacological properties of SUVN-I6107 in various animal models of cognitive deficits at the Alzheimer's Association International Conference (AAIC) 2025. Read More
Vrise Therapeutics Inc. has discovered ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer. Read More
Systimmune Inc. has synthesized antibody-drug conjugates comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer. Read More
In an effort to develop next-generation treatments for cystinuria, researchers at Vanderbilt University and Tennessee Valley Health Services have used a non-viral piggyBac transposon approach to insert the Slc3a1 gene into one kidney of mice lacking the endogenous gene, which services as a model of type A cystinuria. Read More
Wavebreak Therapeutics LLC has identified thiazole compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of amyloidosis, Creutzfeldt-Jakob disease, frontotemporal dementia, Gaucher disease, Lewy body dementia, multiple system atrophy, progressive supranuclear palsy and Parkinson’s disease, among others. Read More
The nucleoside tunicamycin, naturally produced by Streptomyces through fermentation, is widely used as an antibiotic against mycobacteria in livestock, but it often leads to neurological, renal and hepatic toxic effects in cattle, sheep and pigs. Read More
